537 related articles for article (PubMed ID: 33888565)
21. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
[TBL] [Abstract][Full Text] [Related]
23. The MDMX acidic domain competes with the p53 transactivation domain for MDM2 N-terminal domain binding.
Song Q; Liu XQ; Rainey JK
Biochim Biophys Acta Mol Cell Res; 2022 Oct; 1869(10):119319. PubMed ID: 35780910
[TBL] [Abstract][Full Text] [Related]
24. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
25. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
Hu B; Gilkes DM; Farooqi B; Sebti SM; Chen J
J Biol Chem; 2006 Nov; 281(44):33030-5. PubMed ID: 16905541
[TBL] [Abstract][Full Text] [Related]
26. MDM2 and MDMX can interact differently with ARF and members of the p53 family.
Wang X; Arooz T; Siu WY; Chiu CH; Lau A; Yamashita K; Poon RY
FEBS Lett; 2001 Feb; 490(3):202-8. PubMed ID: 11223036
[TBL] [Abstract][Full Text] [Related]
27. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
[TBL] [Abstract][Full Text] [Related]
28. The Roles of MDM2 and MDMX in Cancer.
Karni-Schmidt O; Lokshin M; Prives C
Annu Rev Pathol; 2016 May; 11():617-44. PubMed ID: 27022975
[TBL] [Abstract][Full Text] [Related]
29. Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.
Ohtsubo C; Shiokawa D; Kodama M; Gaiddon C; Nakagama H; Jochemsen AG; Taya Y; Okamoto K
Cancer Sci; 2009 Jul; 100(7):1291-9. PubMed ID: 19432880
[TBL] [Abstract][Full Text] [Related]
30. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
31. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
Wang X
Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
[TBL] [Abstract][Full Text] [Related]
32. p53 binds the mdmx mRNA and controls its translation.
Tournillon AS; López I; Malbert-Colas L; Findakly S; Naski N; Olivares-Illana V; Karakostis K; Vojtesek B; Nylander K; Fåhraeus R
Oncogene; 2017 Feb; 36(5):723-730. PubMed ID: 27375027
[TBL] [Abstract][Full Text] [Related]
33. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
34. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
35. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
[TBL] [Abstract][Full Text] [Related]
36. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.
Jacob AG; Singh RK; Comiskey DF; Rouhier MF; Mohammad F; Bebee TW; Chandler DS
PLoS One; 2014; 9(8):e104444. PubMed ID: 25105592
[TBL] [Abstract][Full Text] [Related]
37. Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner.
Zhang Y; Zeng SX; Hao Q; Lu H
Dev Biol; 2017 Mar; 423(1):34-45. PubMed ID: 28118981
[TBL] [Abstract][Full Text] [Related]
38. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade M; Wahl GM
Mol Cancer Res; 2009 Jan; 7(1):1-11. PubMed ID: 19147532
[TBL] [Abstract][Full Text] [Related]
39. Mdm2 and MdmX partner to regulate p53.
Wang X; Jiang X
FEBS Lett; 2012 May; 586(10):1390-6. PubMed ID: 22673503
[TBL] [Abstract][Full Text] [Related]
40. Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
Garcia D; Warr MR; Martins CP; Brown Swigart L; Passegué E; Evan GI
Genes Dev; 2011 Aug; 25(16):1746-57. PubMed ID: 21852537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]